MangoGen Pharma is a bio-engineering company that is a spin-out of McGill University, Montréal, Québec, Canada. MangoGen Pharma has patented platform technology that describes a method of gene delivery using encapsulated genetically-modified baculoviruses (insect virus) coated on to a medical device (e.g. cardiac stent) or formulated in a cream. Encapsulation is important, as it protects the virus from rapid deactivation by our immune system. On deployment of the medical device, the coating dissolves and the baculovirus is right next to the target cells or tissue. TARGETED DELIVERY. Note: The delivered human gene is only TRANSIENTLY expressed (days), the baculovirus itself does not illicit an immune response and DOES NOT replicate in mammalian cells. The goal is to accelerate wound repair be it around a cardiac stent (re-endothelialization), or accelerate wound repair of a surgical or accidental wound on the skin or debilitating conditions such as diabetic foot ulcers.